Inspire Dental Wellness specializes in the non-surgical treatment of craniofacial pain to help patients improve their quality of life.
…
The post Inspire Dental Wellness Highlights TMJ Therapy, the Minimally Invasive Solution to Craniofacial Pain first appeared on Enrose Magazine.
DEXIS IOS Solutions is pleased to announce the expansion of its portfolio and ecosystem through new digital end-to-end workflows. Dental Practitioners can now easily expand their range of services through aligner and d…
The post DEXIS IOS Solutions Expands Its Portfolio and Ecosystem, Bringing New End-to-End Digital Workflows to Dental Practitioners first appeared on Enrose Magazine.
Dr. Todd Lanman
SAN FRANCISCO, June 12, 2023 (Newswire.com)
–
Todd Lanman, MD, of Lanman Spinal Neurosurgery and ADR Spinal Restoration Center, gave se…
The post Dr. Todd Lanman Presents the Latest Developments in Lumbar Facet Replacement and Periprosthetic Osteolysis Management, 7-Year M6-C IDE Results at ISASS23 first appeared on Enrose Magazine.
The leading online ADHD treatment platform brings in Herman, who has more than two decades of managed care and pharmaceutical experience and is one of the leading experts in behavioral health.
…
The post ADHD Online Welcomes Dr. Barry Herman as Chief Medical Officer first appeared on Enrose Magazine.
GAINESVILLE, Fla., June 12, 2023 (Newswire.com)
–
Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”).
“This is an important milestone for Neobiosis and we are excited to be advancing ViXome, a refined product extracted from thoroughly screened and sterile amniotic fluid obtained at the time of c-section of at-term pregnancies, into clinical development,” said Ian A. White, Ph.D., CEO and CSO of Neobiosis. “We are eager to confirm our preclinical data in the clinic and expect to begin enrolling patients in Phase 1 during the second quarter of 2024.”
ViXome, an acellular product derived from amniotic fluid, contains a heterogeneous population of growth factors, cytokines, chemokines, microRNAs and exosomes, which in pre-clinical testing has demonstrated potent immunomodulatory and pro-reparative effects.
The Phase I/IIa study will thoroughly investigate the safety and clinical efficacy of ViXome. Neobiosis products are processed in state-of-the-art, FDA-registered and FDA-inspected cGMP-compliant cleanrooms in Gainesville, FL. Neobiosis performs its research and development (R&D) at the University of Florida (UF) Sid Martin Innovate Biotechnology Institute in Alachua, FL., the world-recognized leader in biotechnology incubation.
“We are excited to be one of the first companies in the US to advance a potential therapeutic for the treatment of a devastating disease that already affects over 300 million people worldwide,” added Dr. White.
About Neobiosis
Neobiosis is a clinical-stage biopharmaceutical company pioneering the development of perinatal tissue-derived therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical needs. By leveraging the biology of birth tissues as a natural source of regenerative and immunomodulatory cells, matrix and exosomes, Neobiosis has developed its proprietary platform to augment the innate properties of homeostasis to create a portfolio of novel therapeutic candidates. Neobiosis is dedicated to transparency, safety and efficacy of all of its products developed under FDA oversight.
Contact Information:
ian white
CEO
3059062345
Original Source:
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
The post Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’ first appeared on Enrose Magazine.
Release of Fortifeye Healthy Weight Loss Bundle
Dr. Michael Lange Dr. Michael Lange empowers many on healthy weight loss
…
The post Fortifeye Vitamins and Dr. Michael Lange Empower Global Audience with Effective Strategies for Healthy Weight Loss first appeared on Enrose Magazine.
Oasis Psychiatric Day Program Achieves Prestigious Behavioral Health Care and Human Services Accreditation from The Joint Commission
Oasis PDP Logo…
The post Partial Hospital Program Now Open: Comprehensive Mental Health Care Available for Patients first appeared on Enrose Magazine.
DEERFIELD, Ill., June 9, 2023 (Newswire.com)
–
Alera Group, which supports veterinary practices by offering employee benefits and insurance, takes a focused approach to employee benefits and insurance, offering comprehensive solutions designed specifically for veterinary professionals. With a deep understanding of the unique challenges faced by those in the veterinary industry, Alera is committed to providing tailored benefits packages that prioritize the well-being and financial security of veterinary professionals.
Recognizing the crucial role that veterinarians, veterinary technicians, and support staff play in the health and well-being of our beloved pets, Alera has developed an extensive suite of benefits and insurance options to meet their diverse needs. Its innovative platform combines cutting-edge technology with personalized support to simplify the process of accessing and managing these essential resources.
Alera’s employee benefits program includes a wide range of offerings, such as comprehensive health insurance plans, dental and vision coverage, disability insurance, and more. Additionally, Alera partners with leading insurance providers to ensure that veterinary professionals have access to competitive rates and robust coverage options.
“Alera Group’s Veterinary Division is dedicated to supporting veterinary professionals by providing them with the comprehensive benefits and insurance coverage they deserve,” said Cory Friedman, Managing Director at Alera Group. “We understand the unique challenges faced by those in the veterinary industry, and our mission is to alleviate some of that burden by offering customized solutions that protect their health, financial well-being, and peace of mind.”
The Alera Team’s commitment to the veterinary community extends beyond benefits and insurance. They are actively engaged in ongoing research and collaboration with industry partners to develop innovative solutions that address the evolving needs of veterinary professionals.
For more information about Alera and its unique employee benefits and insurance offerings, please visit https://aleravet.com/ or contact Cory Friedman at [email protected].
Contact Information:
Cory Friedman
Managing Director, Veterinary Division
224-628-8682
Original Source:
Alera Group’s Veterinary Division Revolutionizes Employee Benefits and Insurance With Comprehensive Solutions for Animal Hospitals
The post Alera Group’s Veterinary Division Revolutionizes Employee Benefits and Insurance With Comprehensive Solutions for Animal Hospitals first appeared on Enrose Magazine.
INDIANAPOLIS, June 9, 2023 (Newswire.com)
–
Company leaders today announced the launch of 3Aware, formed by leading scientists and technologists from th…
The post MedTech Clinical and Data Science Leaders Come Together to Introduce 3Aware and a First-of-Its-Kind Solution for Post-Market Clinical Follow-Up first appeared on Enrose Magazine.
New Precise™ technology provides physicians with more options for custom PRP
Precise Precise\u2122 – a new advancement in autologous therapies …
The post Isto Biologics Launches Precise – the Newest Advancement in Autologous Therapies first appeared on Enrose Magazine.
